Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials

Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials


As the first investor in M3 Biotechnology, the Alzheimer's Drug Discovery Foundation helped validate the therapeutic potential of M3's drug candidate for Alzheimer's disease. With a second investment of $1.4 million, the ADDF is now providing key funds to support the launch of human trials this year.



from Biotech News